UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053471
Receipt number R000061008
Scientific Title Evaluation of the prototype device for glucose monitoring by oral glucose tolerance test
Date of disclosure of the study information 2024/01/30
Last modified on 2024/03/21 08:43:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of the prototype device for glucose monitoring by oral glucose tolerance test

Acronym

Evaluation of the prototype device for glucose monitoring by oral glucose tolerance test

Scientific Title

Evaluation of the prototype device for glucose monitoring by oral glucose tolerance test

Scientific Title:Acronym

Evaluation of the prototype device for glucose monitoring by oral glucose tolerance test

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm accuracy and characteristics of the blood glucose monitoring device, which is under development, by comparing the data from gold-standard or the date from current simplified glucose monitoring methods.

Basic objectives2

Others

Basic objectives -Others

Correlation between the prototype device and the following blood glucose levels
1.Blood glucose level by venous blood collection
2.Blood glucose level by continuous glucose monitoring.
3.Blood glucose level by self-blood collection (fingertip)

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Comparison of glucose level for each of the prototype devices and venous blood sampling, fingertip sampling and continuous glucose monitoring.

Key secondary outcomes

None


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

4

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Oral glucose(device)

Interventions/Control_2

Oral glucose(continuous glucose monitoring)

Interventions/Control_3

Oral glucose (fingertip sampling)

Interventions/Control_4

Oral glucose (venous blood collection)

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Males and females aged 20 years or older at the time of informed consent.
2) Subjects who can make self-judgment and voluntarily gave written informed consent.
3) Subjects whose fasted blood glucose levels are 100 mg/dL or more and less than 126 mg/dL at a health checkup within the past year.

Key exclusion criteria

1)Subjects who are on treatment for a serious illness.
2)Subjects who have been diagnosed with diabetes and under treatment or medication.
3)Subjects who are may develop allergies in connection with the oral glucose tolerance test.
4)Subjects who regularly use licensed drugs or quasi-drugs that may affect the study.
5)Subjects who are currently on treatment at a medical institution for a disease that may affect the study.
6)Subjects who are participating in a clinical trial or have participated in another clinical trial within 1 month before the date of consent for this study.
7)Subjects who are pregnant and those who are breastfeeding.
8)Subjects who plan to participate in another clinical trial during the study period.
9)Subjects who have difficulty in wearing the prototype device.
10)Subjects who have difficulty in wearing continuous glucose monitoring.
11)Subjects who have difficulty in blood drawing from their fingertips by themselves.
12)Subjects who judged as unsuitable for this study by the principal investigator for any reasons.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Toshio
Middle name
Last name Miyata

Organization

DEN Medical Corporation MIH Clinic Yoyogi.

Division name

Chairman of the board

Zip code

151-0051

Address

2F Value HR Building, 5-21-14 Sendagaya, Shibuya-ku, Tokyo

TEL

03-6276-5385

Email

info@mih-clinic.com


Public contact

Name of contact person

1st name Masako
Middle name
Last name Mizuuchi

Organization

APO PLUS STATION CO., LTD

Division name

CRO Business division

Zip code

103-0027

Address

Front Place Nihonbashi,2-14-1 Nihonbashi, Chuo-ku, Tokyo

TEL

03-6386-8809

Homepage URL


Email

food-contact@apoplus.co.jp


Sponsor or person

Institute

APO PLUS STATION CO., LTD.

Institute

Department

Personal name



Funding Source

Organization

TANITA Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Review Committee, ITO Yoyogi Mental Clinic

Address

4-26-11 Sendagaya, Shibuya-ku, Tokyo

Tel

03-6804-2227

Email

cns_jimu@triad-j.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団DENみいクリニック代々木(東京都)


Other administrative information

Date of disclosure of the study information

2024 Year 01 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2024 Year 01 Month 15 Day

Date of IRB

2024 Year 01 Month 15 Day

Anticipated trial start date

2024 Year 01 Month 30 Day

Last follow-up date

2024 Year 02 Month 29 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 01 Month 29 Day

Last modified on

2024 Year 03 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061008


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name